Aspira Pathlab sets Sep 25 record date for 53rd annual general meeting

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Aspira Pathlab sets book closure from September 19 to 25, 2026
  • The 53rd AGM is scheduled for September 25, 2026, at 2:00 pm
  • E-voting will be open from September 22 to September 24, 2026
  • Cut-off date for shareholding eligibility is September 18, 2026
powered bylight_fuzz_icon
49729725

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab & Diagnostics Limited has set September 19 to September 25, 2026 as the book closure period for its 53rd Annual General Meeting. The meeting is scheduled for September 25, 2026, and will be conducted via video conferencing or other audio-visual means.

The company notified the BSE Limited regarding these dates on August 31, 2026. Shareholders holding equity shares as of the cut-off date of September 18, 2026, will be eligible to vote.

Key Dates for AGM

Event Date/Time
Cut-off date September 18, 2026
Book closure start September 19, 2026
Book closure end September 25, 2026
E-voting start September 22, 2026 at 9:00 am
E-voting end September 24, 2026 at 5:00 pm
AGM date September 25, 2026 at 2:00 pm

Voting Process

The e-voting facility will be available from 9:00 am on September 22, 2026, until 5:00 pm on September 24, 2026. The general meeting adheres to guidelines issued by the Ministry of Corporate Affairs and SEBI circulars regarding remote participation.

Neetu Maurya, Company Secretary & Compliance Officer, issued the intimation. The company’s registered office is located in Mumbai.

Historical Stock Returns for Aspira Pathlab

1 Day5 Days1 Month6 Months1 Year5 Years
-1.32%+2.27%-23.83%+57.89%+47.32%+53.45%

What key financial resolutions or strategic initiatives are expected to be tabled at Aspira Pathlab's 53rd AGM?

How might the company's recent performance in the diagnostics sector influence shareholder voting patterns during the upcoming AGM?

Are there any anticipated changes to the board of directors or executive compensation structures to be discussed at the meeting?

Aspira Pathlab promoter Jay Arvind Bhanushali acquires 332 shares

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Promoter Jay Arvind Bhanushali acquired 332 equity shares in Aspira Pathlab & Diagnostics Ltd.
  • The purchase was made via the open market on August 25, 2026.
  • Bhanushali's stake increased from 7.23% to 7.24% of the total voting capital.
  • Total holdings rose from 7,44,465 to 7,44,797 shares with no encumbrances.
powered bylight_fuzz_icon
49441161

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab promoter Jay Arvind Bhanushali acquired 332 equity shares in the company through the open market on August 25, 2026. The transaction was disclosed to BSE Limited on August 27, 2026, pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Bhanushali’s holding increased from 7,44,465 shares, representing 7.23% of the total voting capital, to 7,44,797 shares, or 7.24%. The acquisition did not involve any encumbered shares, warrants, or convertible securities.

Shareholding Details

The following table outlines the change in Bhanushali’s stake before and after the acquisition:

Metric Before Acquisition After Acquisition
Shares held 7,44,465 7,44,797
Stake percentage 7.23% 7.24%
Encumbered shares 0 0

The total equity share capital of Aspira Pathlab & Diagnostics Ltd remains Rs. 10,29,30,000/-, divided into 1,02,93,000 equity shares of Rs. 10/- each. The diluted share capital also remains unchanged at 1,02,93,000 shares.

Historical Stock Returns for Aspira Pathlab

1 Day5 Days1 Month6 Months1 Year5 Years
-1.32%+2.27%-23.83%+57.89%+47.32%+53.45%

Does this incremental share acquisition signal Jay Arvind Bhanushali's confidence in Aspira Pathlab's upcoming financial performance or strategic initiatives?

How might this slight increase in promoter holding influence retail investor sentiment and short-term stock price volatility?

Are there indications that the promoter is planning further open market purchases to consolidate control or defend against potential takeover bids?

More News on Aspira Pathlab

1 Year Returns:+47.32%